Aadi Bioscience (AADI) Stock Analysis

What Aadi Bioscience does

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.

Key metrics

ETFs linked to AADI

Broad-market and Healthcare sector ETFs an investor holding Aadi Bioscience is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AADI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aadi Bioscience?

Aadi Bioscience trades under the ticker AADI on NASDAQ.

Which exchange is AADI listed on?

AADI is listed on NASDAQ.

What sector does Aadi Bioscience operate in?

Aadi Bioscience is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AADI in a portfolio?

PortView shows AADI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.